GLP-1 & compounded medication availability in Maryland (2026)

Maryland is a permit-first state: the questions its pharmacy regulators care about are whether the pharmacy filling your order holds a Maryland permit, and whether a Maryland-licensed pharmacist is personally answerable for patients here, down to a toll-free number printed on the container you receive. No medication category on this page carries a Maryland-specific restriction on top of that. Here is the full ten-line availability picture for Maryland addresses, gaps included.

Baseline state

Availability facts last reviewed: November 16, 2026

The ten-line picture for Maryland

Availability of all ten OrderlyMeds product lines in Maryland, with typical delivery times and notes
Product lineAvailable in Maryland?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Dispensed by partner pharmacies permitted for Maryland.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days One national price per dose. Baltimore pays what Boise pays.
NAD+ Yes 8–10 business days Ordered through the same online flow as the weight-loss lines.
Sermorelin Yes 8–10 business days Fulfilled by licensed partner pharmacies into all Maryland ZIPs.
Glutathione No N/A Not something OrderlyMeds offers yet; listed so the gap is visible.
BPC-157 Yes 8–10 business days Injectable compound on a patient-specific prescription; see its federal section.
TB-500 Yes 8–10 business days Injectable compound; its federal record is set out below.
KPV No N/A Not stocked in any state, since the peptide formulary here is injectable-only.
Epitalon Yes 8–10 business days Injectable compound; the federal facts below apply in full.
MOTS-c Yes 8–10 business days Injectable compound; note its federal record is distinct, below.

Every row is real data. Where we don’t carry a line, the table says No instead of omitting it. Maryland facts here were last reviewed on November 16, 2026.

Research peptides in Maryland: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Maryland patients can order four of these five lines from OrderlyMeds: BPC-157, TB-500, Epitalon and MOTS-c, all compounded as injectables and dispensed on patient-specific prescriptions. KPV is not among them, because it is not an injectable line and injectables are all we compound in this family. Nothing in Maryland law singles these peptides out, which makes the federal record the whole story, so each line’s own federal facts are stated below, identically on every page in this family, available or not.

BPC-157 in Maryland

Orderable for Maryland addresses as a compounded injectable on a patient-specific prescription, from a pharmacy holding a Maryland permit. Federal facts follow.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Maryland

In the Maryland formulary as a compounded injectable, patient-specific prescription required. The federal record below is required reading.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Maryland

Absent from our formulary everywhere, Maryland included. We do injectable-only peptide compounding, and KPV is not an injectable line.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Maryland

Ships to Maryland as a compounded injectable under a patient-specific prescription. Its federal evaluation history is stated next.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Maryland

Available to Maryland patients as a compounded injectable, patient-specific prescription required. Its federal record stands apart from the other four lines’, so read it below.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Maryland’s pharmacy regulators say about compounded medications

Maryland’s pharmacy oversight runs on permits and named accountability rather than category-level positions. The requirements land on the pharmacy: hold the permit, designate a responsible Maryland-licensed pharmacist, keep the records, print the toll-free line. For a patient ordering through telehealth, that structure is quietly reassuring. It means someone licensed in your state answers for your prescription.

Under Md. Health Occupations §12-403, a nonresident pharmacy dispensing to Maryland patients must hold a pharmacy permit issued by the State Board of Pharmacy, designate a pharmacist licensed by the board as responsible for pharmaceutical services to Maryland patients, and maintain a toll-free patient line at least 40 hours a week, disclosed on the drug container. Source: Md. Health Occupations §12-403.

Maryland applies its drug storage, labeling, prescription-record and sterile-compounding standards (USP 797) to nonresident pharmacies through that permit framework; no GLP-1-specific or peptide-specific restriction has been published by the State Board of Pharmacy. Source: Maryland State Board of Pharmacy.

Maryland permits prescriptions issued on the basis of a telehealth evaluation that meets the same standard of care as an in-person encounter; the non-controlled medications on this page require no prior in-person visit. Source: CCHP Policy Finder — Maryland.

In practice a Maryland order moves exactly like any other OrderlyMeds order: online eligibility check, evaluation by a provider authorized for Maryland, fulfillment by a permitted pharmacy with a tracked shipment inside the published 8–10 business-day window. Pricing never varies by geography, so the number on our pricing page is the Maryland number.

Maryland availability FAQs

Is compounded tirzepatide available in Maryland?

Yes. OrderlyMeds ships compounded tirzepatide (the GLP-1/GIP line) to Maryland addresses at the same flat per-dose price charged in every state.

Who is accountable for my prescription in Maryland?

A named pharmacist licensed by Maryland’s board must be designated as responsible for Maryland patients at any out-of-state pharmacy serving the state, and a toll-free number on your medication container reaches the pharmacy directly. The cited detail sits in the regulator section above.

Can I order BPC-157 or MOTS-c in Maryland?

Both, as compounded injectables on a patient-specific prescription, and TB-500 and Epitalon too. KPV is the one line we carry nowhere. The sections above give each peptide’s cited federal record.

What's the delivery window to Maryland?

8–10 business days from signup, tracked from the moment the pharmacy ships.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone